A
Arnulf Stenzl
Researcher at University of Tübingen
Publications - 854
Citations - 27395
Arnulf Stenzl is an academic researcher from University of Tübingen. The author has contributed to research in topics: Bladder cancer & Prostate cancer. The author has an hindex of 73, co-authored 791 publications receiving 23285 citations. Previous affiliations of Arnulf Stenzl include Ludwig Maximilian University of Munich & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter,Toni Weinschenk,Arnulf Stenzl,Romuald Zdrojowy,Anna Pluzanska,Cezary Szczylik,Michael Staehler,Wolfram Brugger,Pierre-Yves Dietrich,Regina Mendrzyk,Norbert Hilf,Oliver Schoor,Jens Fritsche,Andrea Mahr,Dominik Maurer,Verona Vass,Claudia Trautwein,Peter Lewandrowski,Christian Flohr,Heike Pohla,Janusz J. Stanczak,Vincenzo Bronte,Susanna Mandruzzato,Tilo Biedermann,Graham Pawelec,Evelyna Derhovanessian,Hisakazu Yamagishi,Tsuneharu Miki,Fumiya Hongo,Natsuki Takaha,Kosei Hirakawa,Hiroaki Tanaka,Stefan Stevanovic,Jurgen Frisch,Andrea Mayer-Mokler,Alexandra Kirner,Hans-Georg Rammensee,Carsten Reinhardt,Harpreet Singh-Jasuja +38 more
TL;DR: Among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival are identified.
Journal ArticleDOI
Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines
Arnulf Stenzl,Nigel C. Cowan,Maria De Santis,Markus A. Kuczyk,Axel S. Merseburger,Maria J. Ribal,Amir Sherif,J. Alfred Witjes +7 more
TL;DR: Current data demonstrate that neoadjuvant chemotherapy in conjunction with radical cystectomy (RC) is recommended in certain constellations of MiM-BC, and a new drug for second-line chemotherapy (vinflunine) in metastatic disease has been approved and is recommended.
Journal ArticleDOI
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong,Russell Z. Szmulewitz,Daniel P. Petrylak,Jeffrey M. Holzbeierlein,Arnauld Villers,Arun Azad,Antonio Alcaraz,Boris Alekseev,Taro Iguchi,Neal D. Shore,Brad Rosbrook,Jennifer Sugg,Benoit Baron,Lucy F. Chen,Arnulf Stenzl +14 more
TL;DR: Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with mHSPC, including those with low-volume disease and/or prior docetaxel, with a safety analysis that seems consistent with the safety profile of enzalutamia in previous clinical trials in castration-resistant prostate cancer.
Journal ArticleDOI
Generation of pluripotent stem cells from adult human testis
Sabine Conrad,Markus Renninger,Jörg Hennenlotter,Tina Wiesner,Lothar Just,Michael Bonin,Wilhelm K. Aicher,Hans-Jörg Bühring,Ulrich Mattheus,Andreas F. Mack,Hans-Joachim Wagner,Stephen L. Minger,Matthias Matzkies,Michael Reppel,Jürgen Hescheler,Karl-Dietrich Sievert,Arnulf Stenzl,Thomas Skutella +17 more
TL;DR: The generation of human adult germline stem cells from testicular biopsies may provide simple and non-controversial access to individual cell-based therapy without the ethical and immunological problems associated with human embryonic stem cells.
Journal ArticleDOI
The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer
Arnulf Stenzl,Nigel C. Cowan,Maria De Santis,Gerhard Jakse,M.A. Kuczyk,Axel S. Merseburger,Maria J. Ribal,Amir Sherif,J. Alfred Witjes +8 more
TL;DR: These EAU guidelines are a short, comprehensive overview of the updated guidelines of (MiM-BC) as recently published in theEAU guidelines and also available in the National Guideline Clearinghouse.